Product information and disease description Product description Product information

Product comparison

7 evidence topics · 5 sources

Comparison with ezogabine: potency and daily dose

“azetukalner was estimated to be approximately 50 times more potent than ezogabine” (opens the source at this quote in a new tab)

Comparison with retigabine: daily dose and metabolic burden

“This is evident in the contrasting profiles of retigabine (600–1200 mg/day) and azetukalner (25 mg/day), where the significantly lower dose of azetukalner may reduce the burden on detoxification pathways.” (opens the source at this quote in a new tab)

Comparison with ezogabine: dosing schedule and tolerability limits of the predecessor

“Ezogabine was approved for the treatment of focal seizures in 2011 but, because of the risk of pigmentary changes affecting the retina and the skin, and the consequent need for intensive ophthalmological monitoring, it was never used widely.” (opens the source at this quote in a new tab)
“One factor that probably contributed to ezogabine suboptimal tolerability was its short half-life, which results in considerable fluctuations in serum drug concentrations at steady state. The need for a t.i.d. regimen limited its acceptability in the clinical setting, and retention on treatment was generally lower than that reported for other second-generation ASMs” (opens the source at this quote in a new tab)

Comparison with retigabine: metabolic stability and brain penetration

“This structural analog of retigabine exhibits improved metabolic stability, increased potency, and enhanced blood–brain barrier penetration compared with its predecessor.” (opens the source at this quote in a new tab)

Comparison with currently marketed antiseizure medications: confusional state

“The most frequent TEAEs (dizziness, balance disorder, dysarthria, and gait disturbance) were related to the central nervous system and were similar to those associated with other commonly used ASMs. Some of these TEAEs were dose related and occurred at the highest dose. The adverse event of confusional state occurred at an overall rate of 4.7% in the treated group, which was 3.8% higher than placebo. These rates are similar to the frequencies of the rates observed in placebo-controlled phase 3 trials of lacosamide and oxcarbazepine, and less than the rates in trials of eslicarbazepine, pregabalin, perampanel, and topiramate.” (opens the source at this quote in a new tab)

Mechanistic position relative to the available treatment armamentarium

“Despite a large number of approved epilepsy treatments, there are only a handful of distinct mechanisms of action available, and the data from X-TOLE2 reinforce the value that azetukalner and its KV7 mechanism may bring to the treatment armamentarium for focal seizures” (opens the source at this quote in a new tab)

Comparison with other potassium channel modulators in development

“Related developments include BHV-7000 (BNP-25203), a KV7.2/7.3 modulator in phase II/III for both KCNQ2-DEE (precision use) and focal epilepsy; XEN496, a pediatric retigabine formulation repurposed as precision therapy for KCNQ2-DEE; and AUT-00206, a KV3.1/3.2 modulator in phase II for fragile X syndrome that enhances cortical network synchronization consistent with restored parvalbumin-interneuron function” (opens the source at this quote in a new tab)

Direct comparison with another active antiseizure medication

No evidence found.